The blood-brain barrier is a specialized, semipermeable barrier composed primarily of endothelial cells, pericytes, astrocytes, and extracellular matrix components. It critically regulates the exchange of molecules between the bloodstream and the neural tissue, maintaining central nervous system (CNS) homeostasis. Disruptions in BBB integrity are implicated in numerous neurological disorders, including Alzheimer’s disease, stroke, multiple sclerosis, and brain tumors. Traditional in vitro BBB models, often using primary cells or immortalized lines in two-dimensional cultures, have struggled to recapitulate the multifaceted in vivo environment, limiting their utility in disease modeling and pharmacological testing.

Addressing these limitations, González-Gallego and colleagues constructed their 3D model entirely from iPSCs, which are capable of differentiating into virtually any cell type. The use of iPSCs circumvents ethical issues associated with embryonic stem cells and enables patient-specific disease modeling by generating cells with matched genetic backgrounds. By carefully directing the differentiation of iPSCs into various neurovascular cell types, the researchers integrated endothelial cells, pericytes, and astrocytes into a biomimetic 3D scaffold that reproduces the intricate spatial organization and cellular interactions of the BBB.

Central to the model’s success was the meticulous orchestration of cellular differentiation cues and microenvironmental conditions. The researchers employed a stepwise protocol involving the application of specific growth factors and signaling molecules that mirror embryonic development pathways, guiding iPSCs toward BBB-relevant cell fates. This approach yielded cells exhibiting hallmark functional markers, such as tight junction proteins (claudin-5, occludin) in endothelial cells and the characteristic end-foot structures of astrocytes. Electrophysiological assessments and permeability assays confirmed that the model exhibited robust barrier properties, comparable to those seen in vivo, demonstrating physiological relevance.

What sets this model apart is its three-dimensional architecture. Unlike conventional flat cultures, the 3D scaffold provides a more physiologically accurate representation of the BBB microenvironment, which is pivotal for maintaining functional cell-to-cell communication and proper polarization of endothelial cells. The extracellular matrix composition was carefully tailored to afford mechanical cues and biochemical signals crucial for barrier integrity and cellular vitality. Confocal microscopy revealed a sophisticated network of cellular interactions resembling in vivo neurovascular units, underscoring the model’s fidelity.

The implications of this 3D iPSC-derived BBB model for neuroscience and pharmacology are profound. It presents an unparalleled platform to investigate how pathological conditions disrupt BBB function. Using this system, researchers can model diseases such as neuroinflammation, cerebral ischemia, and neurodegeneration under controlled, reproducible conditions, bypassing the ethical and practical constraints associated with human brain tissue studies. Moreover, the ability to create patient-specific BBB models from iPSCs opens avenues for personalized medicine, allowing evaluation of individual responses to therapeutic compounds and toxicants.

One of the notable applications demonstrated by González-Gallego and colleagues involved subjecting the model to inflammatory stimuli that mimic pathologic states, leading to characteristic BBB breakdown and altered neurovascular signaling. This capability enables detailed mechanistic studies of disease progression and identification of molecular targets for intervention. The platform also proved amenable to high-throughput drug screening, revealing both the protective and deleterious effects of candidate molecules on barrier integrity with remarkable sensitivity.

In addition to disease modeling, the researchers highlighted the model’s potential in facilitating the development of CNS-targeted therapeutics. Historically, one of the substantial hurdles in drug discovery has been the blood-brain barrier itself, which blocks over 98% of small molecule drugs and virtually all large molecules from entering the brain. Screening novel compounds in this physiologically relevant 3D system can accelerate the identification of molecules capable of crossing the BBB safely and effectively, reducing reliance on animal models that often poorly recapitulate human neurovascular physiology.

The model’s incorporation of pericytes and astrocytes alongside endothelial cells is a critical advance. Both pericytes and astrocytes play indispensable roles in regulating BBB function, from controlling tight junction assembly to modulating vascular tone and immune responses. Prior models that neglected these supporting cell types failed to replicate critical dynamics of barrier physiology. This fully integrated cellular milieu provides a realistic environment to dissect intercellular signaling pathways and understand their contributions to barrier maintenance or dysfunction under various conditions.

Another crucial technical achievement was the long-term stability of the model. Maintaining BBB properties over extended periods is essential for chronic disease modeling and repeated drug exposure studies. The 3D system sustained tight barrier function and cellular viability for weeks, offering an experimental window previously unattainable in culture systems. Such longevity also permits time-course investigations of chronic neurovascular insults and therapeutic regimens.

From a translational perspective, this human BBB model aligns with the growing emphasis on reducing animal experimentation and enhancing preclinical model predictivity. It supports the concept of “disease-in-a-dish,” where patient-derived iPSCs can faithfully recapitulate the unique pathophysiology of neurovascular diseases. Furthermore, it fosters collaboration between basic scientists, clinicians, and pharmaceutical developers, creating a nexus for accelerated innovation in neurological therapeutics.

Looking forward, this breakthrough opens multiple avenues for refinement and application. Integration with microfluidic systems to simulate blood flow shear stress, incorporation of immune cells to mimic neuroinflammation faithfully, and coupling with neural organoids to study neurovascular coupling more comprehensively represent exciting frontiers. Additionally, expanding the model’s use to study BBB aging, genetic disorders, and tumor metastasis promises to deepen understanding and treatment of a broad spectrum of CNS conditions.

In summary, the fully iPSC-derived 3D human blood-brain barrier model from González-Gallego et al. constitutes a monumental advance in neurovascular research. By deftly combining stem cell biology, biomaterials engineering, and neurobiology, this study has delivered a versatile, physiologically relevant in vitro tool that captures the complexity of the human BBB. It ushers in a new era of possibility for deciphering disease mechanisms, testing therapeutics, and ultimately improving neurological health outcomes through precision medicine and innovative drug development.

As neurological disorders continue to impose profound societal and economic burdens worldwide, the ability to better model the BBB’s role represents a beacon of hope. This study propels the field toward a future where laboratory models not only mimic human physiology with unprecedented accuracy but also accelerate the journey from bench to bedside. The convergence of stem cell technology and bioengineering demonstrated here exemplifies how interdisciplinary innovation can unlock mysteries of the brain’s protective barriers and spearhead new strategies for combating devastating CNS diseases.

For the neuroscience community and beyond, this fully human 3D BBB model stands as a testament to the power of modern biomedical science and a harbinger of transformative advances in understanding and treating brain disorders. As this platform gains traction and evolves, it promises to become an indispensable asset not only for scientific discovery but also for the development of safer, more effective therapies that cross the elusive blood-brain barrier and improve patients’ lives.

Subject of Research: Development of a fully iPSC-derived 3D model of the human blood-brain barrier for neurovascular disease modeling and therapeutic testing.

Article Title: A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions.

Article References:
González-Gallego, J., Todorov-Völgyi, K., Müller, S.A. et al. A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02123-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-025-02123-w

The BBB is a sophisticated multicellular structure comprising endothelial cells, pericytes, astrocytic endfeet, and the surrounding basement membrane. Each component plays a vital role in maintaining barrier integrity and regulating permeability. Astrocytes, a major glial cell type, intimately ensheathe cerebral microvessels and provide biochemical support that fortifies the endothelial tight junctions essential for BBB function. However, the effect of aging on astrocyte physiology and its subsequent impact on endothelial barrier properties has remained elusive, representing a significant knowledge gap in neurovascular biology. Professor Lo’s team approached this challenge by examining how cellular senescence influences astrocyte signaling to brain endothelial cells.

Central to their investigation was the hypothesis that aging astrocytes upregulate angiotensinogen (AGT), the precursor molecule of angiotensin II (Ang-II), a potent vasoactive peptide known to modulate vascular tone and permeability. Ang-II signaling has been extensively studied in peripheral vasculature but understudied in the context of neurovascular aging. Employing both in vitro co-culture models and conditioned media transfers between astrocytes and endothelial cells, the research demonstrated that young astrocytes robustly enhance endothelial barrier function, whereas senescent astrocytes lose this protective capability. Senescent astrocytes exhibited heightened AGT expression which correlated with increased BBB permeability and altered tight junction protein expression in brain endothelial cells.

To model astrocyte aging, the team used cultures subjected to low and high cumulative population doublings (CPD), representing youthful versus senescent states respectively. Functional assays revealed that endothelial monolayers exposed to senescent astrocytes or their secreted factors displayed significant barrier disruption, characterized by increased passage of albumin and downregulation of key BBB proteins such as occludin and claudin-5. Notably, targeted silencing of AGT in senescent astrocytes via small interfering RNA (siRNA) partially restored endothelial barrier function, implicating elevated AGT and subsequent Ang-II signaling as a causal mechanism in BBB compromise.

These findings illuminate a novel and critical pathway linking cellular aging in astrocytes to vascular dysfunction in the brain’s microenvironment. The elevated production of AGT by senescent astrocytes ultimately translates into paracrine Ang-II activity on endothelial cells, augmenting permeability and undermining BBB integrity. This aberrant signaling cascade offers a plausible molecular explanation for the enhanced BBB leakiness frequently observed in aging and related neurodegenerative conditions. Moreover, the work underscores the importance of astrocyte-endothelial interactions in sustaining neurovascular health and highlights the renin-angiotensin system as a therapeutic target to alleviate age-associated BBB decline.

Considering the wealth of pharmacological tools available to modulate angiotensin signaling, this research paves the way for translational studies aimed at restoring BBB function in elderly populations. Drugs such as angiotensin receptor blockers (ARBs) or ACE inhibitors, currently used in cardiovascular medicine, may hold promise in fortifying the aging neurovascular unit and preventing BBB breakdown. The prospect of repurposing existing therapeutics to mitigate age-related cognitive decline or vascular contributions to dementia is particularly tantalizing and warrants extensive clinical exploration.

Furthermore, the study emphasizes the complexity of the neurovascular unit and its dynamic remodeling during senescence. The interplay between different cell types—astrocytes, endothelial cells, pericytes—and extracellular matrix components evolves over time, influencing cellular communication networks and barrier properties. Age-induced shifts in astrocyte phenotype, including the emergence of pro-inflammatory and reactive states, may also synergize with increased AGT expression to exacerbate neurovascular dysfunction. Future investigations are needed to delineate how astrocyte heterogeneity impacts BBB regulation across the lifespan.

Intriguingly, this research provides a framework to better understand how vascular pathology integrates with classical neurodegenerative processes. BBB leakiness leads to the infiltration of peripheral immune cells, accumulation of neurotoxic blood-derived substances, and disruption of nutrient transport—eventually fostering a hostile microenvironment for neurons. The discovery that astrocyte senescence mediates these changes via angiotensin signaling equips scientists with critical mechanistic insights linking aging, vascular integrity, and brain health.

In summary, Professor Eng H. Lo and colleagues reveal a pivotal role for astrocytic angiotensinogen upregulation in the deterioration of endothelial barrier function within the aging brain. Their meticulous work bridges cellular senescence with molecular pathways impacting BBB permeability and opens promising avenues for intervention. As the global population ages, understanding and targeting neurovascular aging will be indispensable for combating cognitive decline and neurological disorders. This study represents a significant leap forward in decoding the cellular dialogues governing BBB resilience and vulnerability in the aging central nervous system.

Subject of Research: Cells

Article Title: Effects of senescence on astrocyte to brain endothelial cell signaling

News Publication Date: 21-Sep-2025

References:
DOI: 10.1002/nep3.70013

Image Credits: Professor Eng H. Lo from Massachusetts General Hospital and Harvard Medical School

Keywords: Blood brain barrier, Aging, Astrocytes, Angiotensinogen, Neurovascular unit, Endothelial cells, Senescence, Alzheimer’s disease, Neurodegenerative diseases, Brain, Molecular biology, Neuroscience

TDP-43, or TAR DNA-binding protein 43, has predominantly been studied in the context of neurons, where its aggregation and dysfunction are hallmarks of several neurodegenerative disorders. However, the UConn team has identified that reduced levels of TDP-43 in endothelial cells result in significant impairment of the blood-brain barrier’s integrity. Endothelial cells are specialized cells forming a tight monolayer lining the interior surface of blood vessels, and their role is critical in maintaining selective permeability—allowing nutrients to pass while keeping harmful substances from infiltrating brain tissue.

The research underscores that when TDP-43 levels fall below a critical threshold, endothelial cells lose their ability to maintain tight junctions, leading to gaps in the vascular walls. These gaps permit the uncontrolled entry of macromolecules and potentially neurotoxic substances from the bloodstream into the brain parenchyma, thereby accelerating inflammatory responses and neuronal damage. This vascular pathology could contribute directly to the progression and severity of neurodegenerative disease symptoms by disrupting the delicate homeostasis necessary for brain function.

To dissect these mechanisms, the researchers employed sophisticated genetically engineered mouse models. One model harbors a TARDBP mutation linked to familial forms of ALS and frontotemporal dementia, while the second model features targeted deletion of TDP-43 specifically in endothelial cells, sparing neurons and glial cells. Both models exhibited pronounced signs of blood-brain barrier breakdown, evidenced by increased vascular permeability and infiltration of inflammatory cells into brain tissue. These pathological changes were accompanied by behavioral deficits consistent with neurological dysfunction.

These findings expand the scope of TDP-43’s pathological impact beyond neurons, suggesting that its dysregulation in non-neuronal cells plays a substantial role in disease pathogenesis. The presence of TDP-43 aggregates in endothelial cells and ensuing barrier compromise may help explain the phenotypic variability observed clinically—for example, the differing degrees of paralysis in ALS compared to cognitive impairment in frontotemporal dementia, despite overlapping genetic underpinnings.

Remarkably, most cases of ALS and frontotemporal dementia lack identifiable mutations in the TARDBP gene, yet still exhibit TDP-43 protein dysfunction. This observation points to the existence of additional, as yet unidentified endogenous or environmental factors that may disrupt TDP-43 function. Dr. Ashok Cheemala, a lead investigator on the project, emphasizes the need to explore these non-genetic contributors. The team aims to uncover other genetic or molecular regulators whose dysfunction could provoke TDP-43 anomalies in endothelial cells, offering novel therapeutic targets to mitigate disease progression.

An intriguing facet of TDP-43 pathology is its prion-like behavior: the protein tends to misfold and aggregate, forming intracellular inclusions reminiscent of infectious proteins that propagate dysfunction through cell-to-cell transmission. The researchers are actively investigating whether TDP-43 dysfunction in endothelial cells can spread to adjacent neuronal and glial populations. Since the blood vessels are intimately intertwined with neurons and astrocytes, the possibility of a pathogenic cascade initiated by the endothelium holds significant implications for understanding disease chronology and intercellular communication.

Early dysfunction of endothelial TDP-43 might thus represent a critical initiating event in neurodegenerative disease pathogenesis, disrupting vascular integrity before substantial neuronal loss occurs. Unraveling the molecular basis of this early endothelial involvement could transform therapeutic strategies focused on preserving or restoring the blood-brain barrier’s protective function—a compelling avenue to slow or halt the advance of ALS, frontotemporal dementia, and Alzheimer’s disease.

Equally important, the UConn researchers propose that therapeutic approaches targeting endothelial cell health could complement neuron-centric treatments, addressing the multifaceted nature of neurodegeneration. Protecting the vasculature may not only reduce neuroinflammation and toxin infiltration but also maintain the brain’s metabolic and signaling environment conducive to neuronal survival.

The study draws upon extensive experimental methodologies, including transgenic mouse models, immunohistochemistry, in vivo imaging of vascular permeability, and behavioral assays, rendering a comprehensive portrait of the pathological cascade triggered by TARDBP mutations at the cellular and systems levels. These data collectively emphasize the indispensable role of endothelial TDP-43 in neurovascular homeostasis and disease.

This paradigm shift opens new scientific frontiers in neurological research, urging a broader investigation of how blood-brain barrier integrity intersects with proteinopathies characteristic of neurodegenerative diseases. It also highlights the imperative for cross-disciplinary collaboration between vascular biology, neurology, and molecular genetics to unravel the complex etiology of these disorders.

Looking forward, the University of Connecticut team is poised to delve deeper into the molecular events that provoke TDP-43 dysfunction in endothelial cells absent genetic mutations and to identify genetic modifiers that might confer vulnerability or resilience. Such knowledge promises to accelerate the development of innovative therapeutics targeting early disease mechanisms, potentially yielding significant clinical benefits for patients grappling with these currently incurable brain diseases.

The implications of this study resonate beyond the lab, offering hope that addressing vascular contributions and protein dysfunction in unison could redefine the approach to some of the most devastating neurodegenerative conditions known to medicine.

Subject of Research: Animals

Article Title: Amyotrophic lateral sclerosis and frontotemporal dementia mutation reduces endothelial TDP-43 and causes blood-brain barrier defects

News Publication Date: 16-Apr-2025

Web References: 10.1126/sciadv.ads0505

Keywords: Neurological disorders, Amyotrophic lateral sclerosis, Neurodegenerative diseases, Alzheimer disease